Canadian Government's Poor Relationship with Biopharmaceutical Industry

  • 📰 TheHillTimes
  • ⏱ Reading Time:
  • 33 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 79%

Healthcare News

Canada,Government,Biopharmaceutical Industry

The already strained relationship between Canadian governments and the biopharmaceutical industry will be further damaged if the Liberals give in to the NDP's demands for single-payer universal pharmacare. The government's hostility towards the industry is evident in the barriers faced by drug developers and the lack of transparency in health technology assessments and price negotiations.

If the Liberals cave to the NDP’s demands to create single-payer universal pharmacare in order to maintain the supply-and-confidence agreement, the already poor relationship between Canadian governments and the biopharmaceutical industry will be further damaged especially if only so-called “essential” drugs are covered, and not innovative emerging therapies.

Government hostility to the industry is demonstrated by the barriers that drug developers must overcome to get new medicines listed in government drug plans. This includes a lack of federal incentives to submit medicines to Health Canada, protracted health technology assessments (HTAs) that lack accountability and transparency, and slow collective price negotiations. Neither HTAs nor price negotiations provide for independent adjudication of differing views by arbitration or the courts. Even when drugs successfully pass these barriers, government drug plan gatekeepers make the situation worse by slow-walking drugs onto formularie

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 11. in BUSİNESS

Business Business Latest News, Business Business Headlines